Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-01 7:54 pm Unchanged |
2024-10-31 | 13D | Singular Genomics Systems, Inc. OMIC |
James E. Flynn | 249,495 6.660% |
0 (Unchanged) |
Filing History |
| 2024-10-25 5:45 pm Purchase |
2024-10-18 | 13G | Embecta Corp. EMBC |
James E. Flynn | 3,075,335 5.330% |
3,075,335 (New Position) |
Filing History |
| 2024-09-20 6:00 pm Purchase |
2024-09-13 | 13G | Foghorn Therapeutics Inc. FHTX |
James E. Flynn | 2,935,295 5.310% |
2,935,295 (New Position) |
Filing History |
| 2024-09-12 4:07 pm Purchase |
2024-09-05 | 13D | Singular Genomics Systems, Inc. OMIC |
James E. Flynn | 249,495 6.660% |
249,495 (New Position) |
Filing History |
| 2024-07-11 6:47 pm Purchase |
2024-07-09 | 13D | BiomX Inc. PHGE |
James E. Flynn | 15,558,445 9.990% |
14,947,435 (+2446.35%) |
Filing History |
| 2024-05-30 7:26 pm Unchanged |
2024-05-30 | 13D | BiomX Inc. PHGE |
James E. Flynn | 611,010 8.750% |
0 (Unchanged) |
Filing History |
| 2024-05-17 5:14 pm Purchase |
2024-05-07 | 13G | Alignment Healthcare, Inc. ALHC |
James E. Flynn | 10,865,513 5.680% |
10,865,513 (New Position) |
Filing History |
| 2024-05-15 6:39 pm Purchase |
2024-05-15 | 13G | Nuvalent, Inc. NUVL |
James E. Flynn | 25,579,890 33.990% |
102,114 (+0.40%) |
Filing History |
| 2024-04-24 5:50 pm Purchase |
2024-04-18 | 13G | Cullinan Oncology, Inc. CGEM |
James E. Flynn | 3,283,824 5.710% |
3,283,824 (New Position) |
Filing History |
| 2024-04-04 12:52 pm Purchase |
2024-03-15 | 13G | Ventyx Biosciences, Inc. VTYX |
James E. Flynn | 3,542,000 5.030% |
3,542,000 (New Position) |
Filing History |
| 2024-03-22 5:44 pm Purchase |
2024-03-15 | 13D | BiomX Inc. PHGE |
James E. Flynn | 611,010 11.060% |
611,010 (New Position) |
Filing History |
| 2024-03-15 4:37 pm Purchase |
2024-03-14 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 21,273,474 33.320% |
8,300 (+0.04%) |
Filing History |
| 2024-02-16 2:11 pm Purchase |
2024-02-16 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 21,265,174 34.820% |
4,291,539 (+25.28%) |
Filing History |
| 2024-02-15 5:20 pm Unchanged |
2024-02-13 | 13D | Larimar Therapeutics, Inc. LRMR |
James E. Flynn | 16,973,635 39.200% |
0 (Unchanged) |
Filing History |
| 2024-02-12 5:34 pm Purchase |
2023-12-31 | 13G | Nuvalent, Inc. NUVL |
James E. Flynn | 25,477,776 35.010% |
6,110 (+0.02%) |
Filing History |
| 2024-02-12 5:33 pm Sale |
2023-12-31 | 13G | Nuo Therapeutics, Inc. AURX |
James E. Flynn | 2,183,164 5.160% |
-516,836 (-19.14%) |
Filing History |
| 2024-02-12 5:33 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
James E. Flynn | 5,312,733 7.150% |
938,689 (+21.46%) |
Filing History |
| 2024-02-12 5:32 pm Purchase |
2023-12-31 | 13G | Merus N.V. MRUS |
James E. Flynn | 3,019,901 5.230% |
639,463 (+26.86%) |
Filing History |
| 2024-02-12 5:32 pm Purchase |
2023-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
James E. Flynn | 5,788,024 7.190% |
1,160,714 (+25.08%) |
Filing History |
| 2024-02-12 5:31 pm Purchase |
2023-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
James E. Flynn | 8,888,901 8.340% |
3,004,453 (+51.06%) |
Filing History |